Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer

By Smorenburg C.H.   ten Tije A.J.   Verweij J.   Bontenbal M.   Mross K.   van Zomeren D.M.   Seynaeve C.   Sparreboom A.  

European Journal of Cancer, Vol. 39, Iss. 2, 2003-01 ,pp. : 196-202

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer

By Kasai T.   Oka M.   Soda H.   Tsurutani J.   Fukuda M.   Nakamura Y.   Kawabata S.   Nakatomi K.   Nagashima S.   Takatani H.   Fukuda M.   Kinoshita A.   Kohno S.  

European Journal of Cancer, Vol. 38, Iss. 14, 2002-09 ,pp. : 1871-1878

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

By Kobayashi Michiya   Oba Koji   Sakamoto Junichi   Kondo Ken   Nagata Naoki   Okabayashi Takehiro   Namikawa Tsutomu   Hanazaki Kazuhiro  

Gastric Cancer, Vol. 10, Iss. 1, 2007-02 ,pp. : 52-57

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients

By Lu Jian-Feng   Claret Laurent   Sutjandra Liviawati   Kuchimanchi Mita   Melara Rebeca   Bruno René   Sun Yu-Nien  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1151-1158

Springer Publishing Company

Access to resources Recommend Favorite

Plasma c-erbB2 Concentrations in Relation to Chemotherapy in Breast Cancer Patients

By Revillion F.   Hebbar M.   Bonneterre J.   Peyrat J.P.  

European Journal of Cancer, Vol. 32, Iss. 2, 1996-02 ,pp. : 231-234

Elsevier

Access to resources Recommend Favorite